VTGN: Improved financials and promising clinical signals for fasedienol, with cash runway into 2027Quartr·Aug 14 at 07:47 AMVTGN-1.60%
Vistagen Therap | 8-K: FY2027 Q1 Revenue Beats Estimate at USD 1.476 MEarnings Watch·Aug 14 at 07:42 AMVTGN-1.60%
VistaGen FY27 Q1 net loss narrows to $13.03 million; revenue rises to $1.48 millionPUBT·Aug 14 at 07:33 AMVTGN-1.60%
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update | VTGN Stock NewsStockTitan·Aug 13 at 11:32 PMVTGN-1.60%
The Survival Game: Which of These 10 Outlier Equities Are Asleep at the Wheel?Global Report·Aug 7 at 04:18 AMCTNT0.00%O.PR0.00%
VistaGen says Phase 2 repeat-dose fasedienol study in social anxiety disorder shows favorable safety, efficacy signalsPUBT·Aug 6 at 07:34 AMVTGN-1.60%
The Market's Island of Misfit Toys: Who's Faking It and Who's Actually Making MoneyGlobal Report·Aug 6 at 04:15 AMNYT+0.06%NWL+4.93%
VistaGen gets Nasdaq extension to regain $1 minimum bid price compliancePUBT·Aug 5 at 03:28 PMVTGN-1.60%
Commercialization Crunch: The Inside Scoop on 7 US Biotech PipelinesGlobal Report·Aug 5 at 04:13 AMVRTX-1.07%GENB-2.79%
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) | SRXH Stock NewsStockTitan·Aug 3 at 08:00 PMVTGN-1.60%SRXH-2.29%
